Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic
Open accessPublished version of a preprint
Abstract
ABSTRACT Background Isolated REM sleep behavior disorder (iRBD), a reliable prodromal stage marker of α-synucleinopathies like Parkinson’s disease or Lewy body dementia, offers an early window for disease-modifying intervention. Current treatments of iRBD, including the two level B therapies with clonazepam and melatonin, are considered symptomatic. However, numbers of reported patients treated with melatonin are low and whether melatonin has disease-modifying potential is unclear. Methods This single-center, prospective cohort study included 206 consecutive patients diagnosed with iRBD until January 2020. Thirty-nine patients had applied mixed treatments on the advice of the referring physician, 167 had administered melatonin according to our chronobiotic protocol (low dose, ≥ 6 months, always-at-the-same-clock-time , between 10 and 11 pm - corrected for chronotype), which differs from existing melatonin prescriptions. Clinical examination to determine phenoconversion was performed from October 2018 to August 2020. To evaluate generalizability, we compared factors such as neuropsychological and neuromotor performance, olfactory ability, neurovegetative behavior, and dopamine transporter density in our patients with those reported for other cohorts. Primary outcome was phenoconversion to clinical synucleinopathy, assessed using Kaplan-Meier analysis. Secondary outcomes were changes in cognitive and motor performance, and in RBD-symptom severity, analyzed using mixed models. Results RBD characteristics were comparable to those in other published cohorts, including frequency of phenoconversion in our patients with mixed treatments (10/39; follow-up 3.1±2.1 years). In contrast, long-term melatonin-treated patients rarely converted (4/167; follow-up 4.2±3.1 years; hazard-ratio 0.07, 95% CI, 0.02-0.22, p<0.001). Neuromotor and neuropsychological performance did not decline, improved in some domains. Symptom severity gradually improved over the first 4 weeks of treatment (Clinical Global Impression Severity: 5.7 vs. 3.0) and remained stable over years, also in those patients who had stopped melatonin intake after 6 months. The initial response was slower in patients with melatonin suppressing (beta blockers) or REM sleep spoiling co-medication (antidepressants) and failed with inadequate timing of melatonin intake. Conclusion Clock-timed melatonin treatment in patients with iRBD appears to be associated with a marked reduction in the development of parkinsonism and dementia as well as with an improvement in neuromotor, cognitive, and specific RBD symptoms. Findings suggest that melatonin treatment may have disease-modifying effects in synucleinopathies. The fact that melatonin is available anywhere at low cost provides the perspective of immediate clinical application in patients at risk for clinical synucleinopathy. On the other hand, clock-time dependency challenges existing prescription guidelines for melatonin. Melatonin should be acknowledged as the darkness signal to circadian clock-work rather than a hypnotic.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Melatonin supplementation has shown promise in a rare sleep disorder, idiopathic REM Behavior Disorder (iRBD).
“Melatonin supplementation has shown promise in a rare sleep disorder, idiopathic REM Behavior Disorder (iRBD).”
From Is Melatonin the “Next Vitamin D”?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements (2022) · cites this paper as [94]
In one study, six months of low-dose 2 mg melatonin supplementation taken at the same clock time (between 10-11 pm, personalized to the individual's chronotype) resulted in a decrease in iRBD symptom severity over the first four weeks of treatment.
“In one study, six months of low-dose 2 mg melatonin supplementation taken at the same clock time (between 10–11 pm, personalized to the individual’s chronotype) resulted in a decrease in iRBD symptom severity over the first four weeks of treatment.”
From Is Melatonin the “Next Vitamin D”?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements (2022) · cites this paper as [94]
The improvement in iRBD symptom severity was maintained over the follow-up period of 4.2 ± 3.1 years.
“This improvement was maintained over the follow-up period of 4.2 ± 3.1 years [94].”
From Is Melatonin the “Next Vitamin D”?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements (2022) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536 · see citing works
(2007) · Cited by 6,530 · see citing works
Sleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411 · see citing works
Likert scales, levels of measurement, and the “laws” of statistics
Norman, G. (2010) · Advances in Health Sciences Education · doi:10.1007/s10459-010-9222-y · Cited by 4,850 · see citing works
Hypothalamic regulation of sleep and circadian rhythms
Saper, C. B., Scammell, T. E., & Lu, J. (2005) · Nature · doi:10.1038/nature04284 · Cited by 2,804 · see citing works
Hummel, T., Sekinger, B., Wolf, S. R., Pauli, E., & Kobal, G. (1997) · Chemical Senses · doi:10.1093/chemse/22.1.39 · Cited by 2,501 · see citing works
Dijk, D., & Czeisler, C. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03526.1995 · Cited by 1,356 · see citing works
Sleep Cycle Oscillation: Reciprocal Discharge by Two Brainstem Neuronal Groups
Hobson, J. A., McCarley, R. W., & Wyzinski, P. (1975) · Science · doi:10.1126/science.1094539 · Cited by 1,238 · see citing works
Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep
Fultz, N. E., Bonmassar, G., Setsompop, K., Stickgold, R. A., Rosen, B. R., Polimeni, J. R., & Lewis, L. D. (2019) · Science · doi:10.1126/science.aax5440 · Cited by 1,197 · see citing works
Chronic Behavioral Disorders of Human REM Sleep: A New Category of Parasomnia
Schenck, C. H., Bundlie, S. R., Ettinger, M. G., & Mahowald, M. W. (1986) · SLEEP · doi:10.1093/sleep/9.2.293 · Cited by 1,156 · see citing works
Postuma, R. B., Iranzo, Á., Hu, M., Högl, B., Boeve, B. F., Manni, R., Oertel, W. H., Arnulf, I., Ferini‐Strambi, L., Puligheddu, M., et al. (2019) · Brain · doi:10.1093/brain/awz030 · Cited by 1,126 · see citing works
Self-citationSchenck, C. H., Bundlie, S. R., & Mahowald, M. W. (1996) · Neurology · doi:10.1212/wnl.46.2.388 · Cited by 1,083 · see citing works
The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument
Stiasny‐Kolster, K., Mayer, G., Schäfer, S., Möller, J. C., Heinzel‐Gutenbrunner, M., & Oertel, W. H. (2007) · Movement Disorders · doi:10.1002/mds.21740 · Cited by 1,065 · see citing works
Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT
Jeukens‐Visser, M., Marinus, J., Stiggelbout, A. M., & van Hilten, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20153 · Cited by 841 · see citing works
Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.009 · Cited by 814 · see citing works
The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
Holth, J. K., Fritschi, S. K., Wang, C., Pedersen, N. P., Cirrito, J. R., Mahan, T. E., Finn, M. B., Manis, M., Geerling, J. C., Fuller, P. M., et al. (2019) · Science · doi:10.1126/science.aav2546 · Cited by 813 · see citing works
Circadian control of brain glymphatic and lymphatic fluid flow
Hablitz, L. M., Plá, V., Giannetto, M., Vinitsky, H. S., Stæger, F. F., Metcalfe, T., Nguyen, R., Benrais, A., & Nedergaard, M. (2020) · Nature Communications · doi:10.1038/s41467-020-18115-2 · Cited by 704 · see citing works
Melatonin Shifts Human Orcadian Rhythms According to a Phase-Response Curve
Lewy, A. J., Ahmed, S., Jackson, J. M. L., & Sack, R. L. (1992) · Chronobiology International · doi:10.3109/07420529209064550 · Cited by 693 · see citing works
Boeve, B. F. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05115.x · Cited by 642 · see citing works
Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients
Iranzo, A., Fernández-Arcos, A., Tolosa, E., Serradell, M., Molinuevo, J. L., Valldeoriola, F., Gelpi, E., Vilaseca, I., Sánchez-Valle, R., Lladó, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089741 · Cited by 548 · see citing works
Polysomnographic features of REM sleep behavior disorder
Lapierre, O., & Montplaisir, J. Y. (1992) · Neurology · doi:10.1212/wnl.42.7.1371 · Cited by 503 · see citing works
Aurora (2010) · doi:10.5664/jcsm.27717 · Cited by 463 · see citing works
Update on melatonin receptors: IUPHAR Review 20
Jockers, R., Delagrange, P., Dubocovich, M. L., Markus, R. P., Renault, N., Tosini, G., Cecon, E., & Zlotos, D. P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13536 · Cited by 426 · see citing works
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
Mittal, S., Bjørnevik, K., Im, D. S., Flierl, A., Dong, X., Locascio, J. J., Abo, K. M., Long, E., Jin, M., Xu, B. Y., et al. (2017) · Science · doi:10.1126/science.aaf3934 · Cited by 417 · see citing works
Circadian Melatonin Rhythm and Excessive Daytime Sleepiness in Parkinson Disease
Videnovic, A., Noble, C., Reid, K. J., Peng, J., Turek, F. W., Marconi, A., Rademaker, A. W., Simuni, T., Zadikoff, C., & Zee, P. C. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6239 · Cited by 390 · see citing works
Galbiati, A., Verga, L., Giora, E., Zucconi, M., & Ferini‐Strambi, L. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2018.09.008 · Cited by 372 · see citing works
Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK)
Li, S. X., Wing, Y. K., Lam, S. P., Zhang, J., Yu, M., Ho, C. K. W., Tsoh, J. Y., & Mok, V. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2009.06.008 · Cited by 287 · see citing works
Reiter, R. J., Tan, D., Rosales‐Corral, S., & Manchester, L. C. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557511313030006 · Cited by 274 · see citing works
Iranzo, Á., Santamaría, J., & TOLOSA, E. S. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00057-0 · Cited by 274 · see citing works
Kunz, D., & Mahlberg, R. (2010) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2010.00848.x · Cited by 271 · see citing works
Self-citationVidenovic, A., Klerman, E. B., Wang, W., Marconi, A., Kuhta, T., & Zee, P. C. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5192 · Cited by 255 · see citing works
SNM Practice Guideline for Dopamine Transporter Imaging with 123 I-Ioflupane SPECT 1.0
Djang, D., Janssen, M. J. R., Bohnen, N. I., Booij, J., Henderson, T. A., Herholz, K., Minoshima, S., Rowe, C. C., Sabri, O., Seibyl, J. P., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100784 · Cited by 247 · see citing works
Prodromal Parkinson's Disease: The Decade Past, the Decade to Come
Postuma, R. B., & Berg, D. (2019) · Movement Disorders · doi:10.1002/mds.27670 · Cited by 224 · see citing works
Fernández‐Arcos, A., Iranzo, Á., Serradell, M., Gaig, C., & Santamaría, J. (2015) · SLEEP · doi:10.5665/sleep.5332 · Cited by 223 · see citing works
Iranzo, Á., Santamaría, J., Valldeoriola, F., Serradell, M., Salamero, M., Gaig, C., Niñerola‐Baizán, A., Sánchez‐Valle, R., Lladó, A., Marzi, R. D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25026 · Cited by 213 · see citing works
Melatonin: Clinical Perspectives in Neurodegeneration
Cardinali, D. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00480 · Cited by 202 · see citing works
Precision medicine for disease modification in Parkinson disease
Espay, A. J., Brundin, P., & Lang, A. E. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.196 · Cited by 180 · see citing works
Wyatt, J. K., Dijk, D., Cecco, A. R.-D., Ronda, J. M., & Czeisler, C. A. (2006) · SLEEP · doi:10.1093/sleep/29.5.609 · Cited by 174 · see citing works
Reppert, S. M., & Weaver, D. R. (1995) · Cell · doi:10.1016/0092-8674(95)90131-0 · Cited by 153 · see citing works
Chronobiotics—drugs that shift rhythms
Dawson, D. E., & Armstrong, S. M. (1996) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)02020-9 · Cited by 150 · see citing works
Leng, Y., BLACKWELL, T. L., Cawthon, P. M., Ancoli‐Israel, S., Stone, K. L., & Yaffe, K. S. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1623 · Cited by 142 · see citing works
Gerdin, M. J., Masana, M. I., Rivera-Bermudez, M. A., Hudson, R. L., Earnest, D. J., Gillette, M. U., & Dubocovich, M. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-1339com · Cited by 137 · see citing works
Gilat, M., Jackson, A. C., Marshall, N. S., Hammond, D. A., Mullins, A. E., Hall, J. M., Fang, B., Yee, B. J., WONG, K. K. H., Grunstein, R. R., et al. (2019) · Movement Disorders · doi:10.1002/mds.27886 · Cited by 135 · see citing works
Disease modification and biomarker development in Parkinson disease
Espay, A. J., Kalia, L. V., Gan‐Or, Z., Williams‐Gray, C. H., Bedard, P. L., Rowe, S. M., Morgante, F., Fasano, A. A., Stecher, B., Kauffman, M. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009107 · Cited by 134 · see citing works
Melatonin in Patients with Reduced REM Sleep Duration: Two Randomized Controlled Trials
Kunz, D., Mahlberg, R., Müller, C., Tilmann, A., & Bes, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021057 · Cited by 133 · see citing works
Self-citationCircadian actions of melatonin at the suprachiasmatic nucleus
Gillette, M. U., & McArthur, A. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00085-x · Cited by 127 · see citing works
Schmid, N. S., Ehrensperger, M. M., Berres, M., Beck, I. R., & Monsch, A. U. (2014) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000357774 · Cited by 126 · see citing works
Validation of a Polysomnographic Score for REM Sleep Behavior Disorder
Consens, F. B., Chervin, R. D., Koeppe, R. A., Little, R. J. A., Liu, S., Junck, L., Angell, K., Heumann, M., & Gilman, S. (2005) · SLEEP · doi:10.1093/sleep/28.8.993 · Cited by 123 · see citing works
Sixel‐Döring, F., Schweitzer, M., Mollenhauer, B., & Trenkwalder, C. (2011) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.28044 · Cited by 120 · see citing works
Validation of the Innsbruck REM sleep behavior disorder inventory
Frauscher, B., Ehrmann, L., Zamarian, L., Auer, F., Mitterling, T., Gabelia, D., Brandauer, E., Delazer, M., Poewe, W. H., & Högl, B. (2012) · Movement Disorders · doi:10.1002/mds.25223 · Cited by 116 · see citing works
McCarter, S. J., Louis, E. S., Sandness, D. J., Arndt, K., Erickson, M. K., Tabatabai, G. M., Boeve, B. F., & Silber, M. H. (2015) · Sleep Medicine · doi:10.1016/j.sleep.2015.02.005 · Cited by 107 · see citing works
Samel, A., Wegmann, H.-M., Vejvoda, M., Maass, H., GUNDEL, A., & Schütz, M. (1991) · Journal of Biological Rhythms · doi:10.1177/074873049100600304 · Cited by 106 · see citing works
McCarter, S. J., Louis, E. K. S., Sandness, D. J., Arndt, K., Erickson, M. K., Tabatabai, G. M., Boeve, B. F., & Silber, M. H. (2015) · SLEEP · doi:10.5665/sleep.4738 · Cited by 106 · see citing works
Inducing jet‐lag in older people: Directional asymmetry
Monk, T. H., Buysse, D. J., Carrier, J., & Kupfer, D. J. (2000) · Journal of Sleep Research · doi:10.1046/j.1365-2869.2000.00184.x · Cited by 103 · see citing works
Melatonin — The Hormone of Darkness
Utiger, R. D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271909 · Cited by 95 · see citing works
Loss of response to melatonin treatment is associated with slow melatonin metabolism
Braam, W., Van Geijlswijk, I., Keijzer, H., Smits, M. G., Didden, R., & Curfs, L. M. G. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01283.x · Cited by 94 · see citing works
Clinical trials in REM sleep behavioural disorder: challenges and opportunities
Videnović, A., Ju, Y. S., Arnulf, I., Cock, V. C. D., Högl, B., Kunz, D., Provini, F., Ratti, P., Schiess, M. C., Schenck, C. H., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-322875 · Cited by 94 · see citing works
Self-citationKunz, D., & Bes, F. (2008) · Neuropsychobiology · doi:10.1159/000119383 · Cited by 81 · see citing works
Self-citationvan den Heuvel, C. J., Reid, K. J., & Dawson, D. E. (1997) · Physiology & Behavior · doi:10.1016/s0031-9384(96)00534-3 · Cited by 79 · see citing works
Treatment with beta‐adrenoceptor blockers reduces plasma melatonin concentration.
Cowen, P. J., Bevan, J., Gosden, B., & Elliott, S. (1985) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1985.tb02640.x · Cited by 74 · see citing works
Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism
Darweesh, S. K. L., Wolters, F. J., Postuma, R. B., Stricker, B. H. C., Albert Hofman, D., Koudstaal, P. J., Ikram, M. K., & Ikram, M. A. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2248 · Cited by 73 · see citing works
Exogenous Melatonin in Periodic Limb Movement Disorder: An Open Clinical Trial and a Hypothesis
Kunz, D., & Bes, F. (2001) · SLEEP · doi:10.1093/sleep/24.2.183 · Cited by 67 · see citing works
Self-citationBisoprolol-induced rapid eye movement sleep behavior disorder
Iranzo, Á., & Santamaría, J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00245-4 · Cited by 63 · see citing works
Škorvánek, M., Feketeová, E., Kurtis, M. M., Rusz, J., & Šonka, K. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00376 · Cited by 59 · see citing works
Terzaghi, M., Zucchella, C., Rustioni, V., Sinforiani, E., & Manni, R. (2013) · SLEEP · doi:10.5665/sleep.3050 · Cited by 54 · see citing works
Prolonged–release melatonin in patients with idiopathic REM sleep behavior disorder
Jun, J., Kim, R., Byun, J., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.753 · Cited by 50 · see citing works
Actigraphy: a useful tool to monitor sleep-related hypermotor seizures
Pérez‐Carbonell, L., Silva, C., Matos, N., Gaig, C., Iranzo, Á., & Santamaría, J. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.09.016 · Cited by 48 · see citing works
Bes, F., Jobert, M., MÜLLER, L., & Schulz, H. (1996) · Journal of Sleep Research · doi:10.1046/j.1365-2869.1996.00020.x · Cited by 40 · see citing works
Self-citationKunz, D. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-827167 · Cited by 21 · see citing works
Self-citationEditorial: Circadian Rhythms are Everywhere: Except in Neurodegenerative Disorders
Kunz, D. (2017) · Current Alzheimer Research · doi:10.2174/156720501410170908094658 · Cited by 4 · see citing works
Self-citationKunz, D., & Bes, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-90152-7_24 · Cited by 1 · see citing works
Self-citationLouis (1999) · doi:10.1002/1531-8257(199905)14:3
Flagged first, then by citations
Research works printed but not linked: 2
- GBD 2016 Collaborators Neurology. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459-80.
- Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open- labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999; 14: 507-11.
Cited by
Sorted by citations
Minich, D. M., Henning, M., Darley, C., Fahoum, M., Schuler, C. B., & Frame, J. (2022) · Nutrients · doi:10.3390/nu14193934 · Cited by 176 · see citing works
- Authors
- Kunz, D., Stotz, S., & Bes, F.
- Affiliations
- St. Hedwig-Krankenhaus (DE)
- Clinic for Sleep & Chronomedicine St. Hedwig‐Krankenhaus Berlin Berlin Germany
- Corresponding author
- Kunz, Dieter
- Venue
- Journal of Pineal Research
- Publisher
- Wiley
- Published
- 2021-08-03
- Volume
- 71
- Issue
- 2
- Pages
- e12759-e12759
- ISSN
- 0742-3098 (ISSN-L)
- 1600-079X
- OpenAlex
- W3186911417
- Cited by
- 42
- References
- 73
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 12 · 2022: 6 · 2021: 3
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Pineal Research (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
- Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- REM sleep behavior disorder, melatonin, beta-blockers, antidepressants, treatment discontinuation, long-term treatment outcomes
- MeSH terms
- Humans, Melatonin, Sleep, REM, Reproducibility of Results, REM Sleep Behavior Disorder
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
